Lexaria Bioscience Corp (LEXX): TIMBER! LXRP CEO exercises 247,500 optio...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	122
Posts	43825
Boards Moderated	1
Alias Born	09/06/2012

236T568

Re: None

Tuesday, 06/19/2018 5:06:44 PM

Tuesday, June 19, 2018 5:06:44 PM

TIMBER! LXRP CEO exercises 247,500 options at $0.09 per share and 450,000 warrants at $0.14 per share

look out below!

https://www.sec.gov/Archives/edgar/data/1103780/000110378018000002/xslF345X03/primary_doc.xml

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent LEXX News

Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/30/2023 09:14:31 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/20/2023 10:16:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 05:13:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 05:45:34 PM
Get Ready for Next Generation of Diabetes, Weight-Management Drugs • InvestorsHub NewsWire • 11/01/2023 12:45:00 PM

More LEXX News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover